Kajian DNA Rekombinan pada Vaksin DNA dan Vaksin Subunit Protein

Tri Panjiasih Susmiarsih


Vaksin telah dikenal sebagai substansi yang digunakan untuk menstimulasi sistem imun. Saat ini, perkembangan vaksin sudah mencapai generasi vaksin DNA dan vaksin subunit protein.Teknologi perancangan  vaksin  digunakan  dalam  mengembangkan berbagai  jenis  vaksin dengan pendekatan biologi molekular yaitu menggunakan teknik DNA rekombinan yang memerlukan sarana vektor, DNA target, enzim restriksi dan ligasi serta sel inang. Studi ini bertujuan mengkaji teknik DNA rekombinan dalam pembuatan vaksin DNA dan vaksin subunit protein.


DNA rekombinan, vaksin, subunit protein

Full Text:



Abdulhaqq SA, Weiner DB. 2008. DNA vaccines: developing new strategies to enhance immune responses. Immunol Res.


Andre FE. 1990. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine. 8(Suppl.): S74-S78 discussion S79–80.

Barouch DH. 2005. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol. 79:8828–34.

Billiau A, Matthys P. 2001. Modes of action of Freund’s adjuvants in experimental models of autoimmune diseases. J. Leukoc. Biol. 70: 849–860.

Brooker RJ. 2005. Genetics: Analysis and principles. Second Edition. McGraw-Hill Companies, Inc., Boston. xxii + 842 hlm.

Bucher MH, Evdokimov AG, Waugh DS. 2002.Differential effects of short affinity tags on the crystallization of Pyrococcus furiosus maltodextrin-binding protein. Biol Cryst. 58:392–397.

Davis LG, Kuehl WM, Battey JF. 1994. Basic methods in molecular biology. Second Edition. Appleton & Lange, Norwalk. xiii + 763 hlm.

Debeljak N, Feldman L, Davis KL, Komel R, Sytkowski AJ. 2006. Variability in the Immuno-detection of His-tagged Recombinant Proteins. Anal Biochem.

(2): 216–223.

Donnelly JJ, Wahren B, Liu MA. 2005. DNA Vaccines: Progress and Challenges. Immunology. 175: 633–639.

Edelman R. 2000. An Overview of Adjuvant Use. Dalam : Methods in molecular medicine . Vaccine adjuvants: preparation methods and research protocols / edited by Derek T. O'Hagan. Humana Press Inc. Totowa New Jersey. 1-27.

Eldridge JH, Staas JK, Meulbroek JA, Tice TR, Gilley RM. 1991. Biodegradable and biocompatible poly (DL-lactide-co- glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxinneutralizing antibodies. Infect Immun. 59(9):2978-86.

Faurez F, Dory D, Le Moigne V, Gravier R, Jestin A. 2010. Biosafety of DNA vaccines: New generation of DNA vectors and current knowledge on the fate of plasmids after injection. Vaccine. 28: 3888–3895

Griffiths AJF, Gelbart WM, Miller JH, Lewontin RC. 1999. Modern genetic analysis. W.H. Freeman Company, New York. xvi + 675 hlm.

Glenting J, Wessel S. 2005. Ensuring safety of DNA vaccines. Microbial Cell Factorie. 4:26.

Hannig G, Makrides SC. 1998. Strategies for optimizing heterologous protein expression in Escherichia coli. Trends Biotechnol.16:54-60.

Hefti MH, Van Vugt-Van der Toorn CJG, Dixon, R., Vervoort, J. 2001. A Novel Purification Method for Histidine-Tagged Proteins Containing a Thrombin Cleavage Site. Anal Biochem. 295:180–185.

Hochuli E, Dobeli A, Schacher A. 1987. New metal chelate adsorbent selective for proteins and peptides containing neighbouring histidine residues. J. Chromatogr. 411:177Y184.

Invitrogen. 2010. Champion™ pET Directional TOPO expression kits. Cat. No K100-01 Invitrogen Corp. California. xiii + 60 hlm.

Janknecht R, de Martynoff G, Lou J, Hipskind, R., Nordheim, A., Stunnenberg, H.G. 1991. Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccina virus. Proc Natl Acad Sci. 88:8972–8976.

Kumar U, Kumar S, Varghese S, Chamoli R, Barthwal P. 2013. DNA vaccine: a modern biotechnological approach towards human welfare and clinical trials. Int J of Research in Biomedicine and Biotechnology 2013;

(1): 17-20.

Lai YF, Tseng YJ, Yang FY, Au LC. 2008. Mammalian cis-reporting plasmid may alter activities due to the derivation of host Escherichia coli strains. Anal Biochem. 376:103–7.

La Vallie ER, Mc Coy JM. 1995. Gene fusion expression systems in Escherichia coli. Current Opinion Biotechnology. 6:501-506

Liljeqvist S, Stahl S. 1999. Production of recombinant subunit vaccines: protein immuno- gens, live delivery systems and nucleic acid vaccines. J Biotech. 73: 1–33.

Lin-Chao S, Chen W, Wong T. 1992. High copy number of the pUC plasmid results from a Rom/Ropsuppressible point mutation in RNAII. Mol Micro. 6:3385–93.

Luke J, Carnes AE, Hodgson CP, Williams JA. 2009. Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection system. Vaccine. 27(46):6454-9.

Mac Gregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, Chattergoon MA, Bain Y, Higgins TJ, Ciccarell RB, Coney LR, Ginsberg RS, Weiner DB. 1998. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis. 1998; 178(1):92-100 .

Mateen I, Irshad, S. 2011. A Review on DNA Vaccines. J Health Sciences. 1(1):1-7.

Nascimento, IP, Leite LCC. 2012. Recombinant vaccines and the development of new vaccine strategies. Braz J Med Biol Res. 45(12):1102-1111.

Nicholl DST. 2002. An introduction to genetic engineering. Second Edition. Cambridge University Press, New York. 2002: xi + 292 hlm.

O’Hagan. 2007. New Generation Vaccine Adjuvants. Encyclopedia Of Life Sciences. John Wiley & Sons, Ltd. www.els.net:1-7.

Pizza M, Covacci A, Bartoloni A, Perugini M, Nencioni L, De Magistris MT, Villa L, Nucci D, Manetti R, Bugnoli M. 1989. Mutants of pertussis toxin suitable for vaccine development. Science. 246:497-500.

Petrovsky N, Aguilar JC. 2004. Vaccine adjuvants: Current state and future trends. Immunol Cell Biol. 82(5):488-96

Radji M. 2011. Rekayasa Genetika; Pengantar untuk Profesi Kesehatan.Sagung Seto: Jakarta.

Ramanathan MP, Ayyavoo V, Weiner DB. 2001. Choice of expression vector alters the localization of a human cellular protein. DNA Cell Biol. 20:101–5.

Rangarajan PN. 2002. DNA Vaccines. Resonance. 25-34.

Reed SG, Orr MT, Fox CB. 2013. Key roles of adjuvants in modern vaccines Nature Medicine. 19:1597-1608.

Snustad DP, Simmons MJ. 2003. Principles of genetics. Third Edition. John Wiley & Sons, Inc. NY. xix + 840 hlm.

Sorensen H, Mortensen K. 2005. Advanced genetic strategies for recombinant protein expression in Escherichia coli. J Biotech.


Strachan T, Read AP. 1999. Human molecular genetics 2. Second Edition. A John Wiley & Sons, Inc., New York. xxiii + 576 hlm.

Studier FW, Moffatt BA. 1986. Use of bacteriophage T7 RNA polymerase to direct selective high level expression of cloned genes. J Mol Biol. 189:113-130.

Tsuchiya H, Matsuda T, Harashima H, Kamiya H. 2005. Cytokine induction by a bacterial DNA-specific modified base. Biochem Biophys Res Commun. 326:777–81. Unnikrishnan M, Rappuoli R, Serruto D. 2012.

Recombinant bacterial vaccines. Current Opinion in Immunology. 24:337–342.

Vogel FR. 2000. Improving Vaccine Performance with Adjuvants. Clinical Infectious Diseases. 30(Suppl 3):S266–70.

Ward WW, Swiatek G. 2009. Protein purification. Current Analytical Chemistry. 5:2 :1-21

Watson JD, Gilman M, Witkowski J, Zoller M. 1992. Recombinant DNA. Second Edition. W.H. Freeman and Company, New York. xiv + 626 hlm.

Williams JA, Carnesa AE, Hodgson CP. 2009. Plasmid DNA Vaccine vector design: impact on efficacy, safety and upstream production.Biotechnol Adv. 27(4): 353–370.

Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A. 1990. Direct gene transfer into mouse muscle in vivo. Science. 247: 1465-1468.

Wolff JA, Ludtke JJ, Acsadi G, Williams P, Jani A. 1992. Longterm persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum. Mol. Gen. 1: 363-369.

Wong DWS. 2007. The ABC of gene cloning. International Thomson Publishing, New York. 2007: xiv + 213 hlm.

Young CA, Britton ZT, Robinson AS. 2012. Recombinant protein expression and purification: A comprehensive review of affinity tags and microbial applications. Biotechnol. J. 7, 620–634.

DOI: http://dx.doi.org/10.33476/mkp.v10i2.730


  • There are currently no refbacks.

P-ISSN: 2085-5648

E-ISSN: 2655-2396